Skip to Content

'
Sara Peleg, Ph.D.

Present Title & Affiliation

Primary Appointment

Associate Professor, Department of Endocrine Neoplasia and Hormonal Disorders - Research, Division of Internal Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX

Dual/Joint/Adjunct Appointment

Member, The University of Texas Graduate School of Biomedical Sciences, Houston, TX

Education & Training

Degree-Granting Education

1982 The Weizmann Institute of Science, Rehovot, Israel, PHD, Endocrinology
1974 Tel Aviv University, Tel Aviv, Israel, MS, Zoology
1971 Tel Aviv University, Tel Aviv, Israel, BS, Biology

Postgraduate Training

1986-1988 Postgraduate Training, Molecular Biology, Baylor College of Medicine, Houston, TX, B.W. O'Malley
1983-1985 Postgraduate Training, Biochemistry, Baylor College of Medicine, Houston, TX, W.T. Schrader

Selected Publications

Peer-Reviewed Original Research Articles
1. Petersen KS, Dolan PM, Kensler TW, Peleg S, Posner GH. Low-calcemic, highly antiproliferative, 23-oxa ether analogs of the natural hormone 1 alpha,25-dihydroxyvitamin D3: design, synthesis, and preliminary biological evaluation. J Med Chem 50(23):5824-32, 11/15/2007. PMID: 17924616.
2. Kittaka A, Saito N, Honzawa S, Takenouchi K, Ishizuka S, Chen TC, Peleg S, Kato S, Arai MA. Creative synthesis of novel vitamin D analogs for health and disease. J Steroid Biochem Mol Biol 103(3-5)(3-5):269-76, 3/2007. PMID: 17223554.
3. Posner GH, Suh BC, Petersen KS, Dolan P, Agoston ES, Kensler TW, Koh JT, Peleg S. Difluoromethyl analogs of the natural hormone 1alpha,25-dihydroxyvitamin D3: Design, synthesis, and preliminary biological evaluation. J Steroid Biochem Mol Biol 103(3-5)(3-5):213-21, 3/2007. PMID: 17218093.
4. Marks HD, Fleet JC, Peleg S. Transgenic expression of the human Vitamin D receptor (hVDR) in the duodenum of VDR-null mice attenuates the age-dependent decline in calcium absorption. J Steroid Biochem Mol Biol 103(3-5)(3-5):213-21, 3/2007. PMID: 17207992.
5. Klopot A, Hance KW, Peleg S, Barsony J, Fleet JC. Nucleo-cytoplasmic cycling of the vitamin D receptor in the enterocyte-like cell line, Caco-2. J Cell Biochem 100(3):617-28, 2/2007. PMID: 16960876.
6. Peleg S. Responsiveness of osteoblastic and osteolytic bone metastases to vitamin D analogs. Crit Rev Eukaryot Gene Expr 17(2):149-158, 2007. PMID: 17725485.
7. Peleg S, Petersen KS, Suh BC, Dolan P, Agoston ES, Kensler TW, Posner GH. Low-calcemic, highly antiproliferative, 1-difluoromethyl hybrid analogs of the natural hormone 1alpha,25-dihydroxyvitamin D3: design, synthesis, and preliminary biological evaluation. J Med Chem 49(25):7513-7, 12/2006. PMID: 17149880.
8. Peleg S, Khan F, Navone NM, Cody DD, Johnson EM, Van Pelt CS, Posner GH. Inhibition of prostate cancer-meditated osteoblastic bone lesions by the low-calcemic analog 1alpha-hydroxymethyl-16-ene-26,27-bishomo-25-hydroxy vitamin D3. J Steroid Biochem Mol Biol 97(1-2):203-11, 10/2005. PMID: 16081281.
9. Phokela SS, Peleg S, Moya FR, Alcorn JL. Regulation of human pulmonary surfactant protein gene expression by 1alpha,25-dihydroxyvitamin D3. Am J Physiol Lung Cell Mol Physiol 289(4):L617-26, 10/2005. PMID: 15951333.
10. Hatcher MA, Peleg S, Dolan P, Kensler TW, Sarjeant A, Posner GH. A-ring hydroxymethyl 19-nor analogs of the natural hormone 1alpha,25-dihydroxyvitamin D3: synthesis and preliminary biological evaluation. Bioorg Med Chem 13(12):3964-76, 6/2005. PMID: 15878279.
11. Posner GH, Lee SH, Kim HJ, Peleg S, Dolan P, Kensler TW. Novel A-ring analogs of the hormone 1alpha,25-dihydroxyvitamin D3: synthesis and preliminary biological evaluation. Bioorg Med Chem 13(8):2959-66, 4/2005. PMID: 15781405.
12. Honzawa S, Hirasaka K, Yamamoto Y, Peleg S, Fujishima T, Kurihara M, Saito N, Kishimoto S, Sugiura T, Waku K, Takayamaa H, and Kittaka. Design, synthesis and biological evaluation of novel 1alpha,25-dihydroxyvitamin D3 analogues possessing aromatic ring on 2alpha -position. Tetrahedron 61:11253-11263, 2005.
13. Swamy N, Chen TC, Peleg S, Dhawan P, Christakos S, Stewart LV, Weigel NL, Mehta RG, Holick MF, Ray R. Inhibition of proliferation and induction of apoptosis by 25-hydroxyvitamin D3-3beta-2-Bromoacetate, a nontoxic and vitamin D receptor-alkylating analog of 25-hydroxyvitamin D3 in prostate cancer cells. Clin Cancer Res 10(23):8018-27, 12/2004. PMID: 15585637.
14. Kahraman M, Sinishtaj S, Dolan PM, Kensler TW, Peleg S, Saha U, Chuang SS, Bernstein G, Korczak B, Posner GH. Potent, selective and low-calcemic inhibitors of CYP24 hydroxylase: 24-sulfoximine analogues of the hormone 1alpha,25-dihydroxyvitamin D3. J Med Chem 47(27):6854-63, 12/2004. PMID: 15615534.
15. Malloy PJ, Xu R, Peng L, Peleg S, Al-Ashwal A, Feldman D. Hereditary 1,25-dihydroxyvitamin D resistant rickets due to a mutation causing multiple defects in vitamin D receptor function. Endocrinology 145(11):5106-14, 11/2004. PMID: 15308610.
16. Posner GH, Crawford KR, Yang HW, Kahraman M, Jeon HB, Li H, Lee JK, Suh BC, Hatcher MA, Labonte T, Usera A, Dolan PM, Kensler TW, Peleg S, Jones G, Zhang A, Korczak B, Saha U, Chuang SS. Potent, low-calcemic, selective inhibitors of CYP24 hydroxylase: 24-sulfone analogs of the hormone 1alpha,25-dihydroxyvitamin D3. J Steroid Biochem Mol Biol 89-90(1-5):5-12, 5/2004. PMID: 15225738.
17. Ismail A, Nguyen CV, Ahene A, Fleet JC, Uskokovic MR, Peleg S. Effect of cellular environment on the selective activation of the vitamin D receptor by 1alpha,25-dihydroxyvitamin D3 and its analog 1alpha-fluoro-16-ene-20-epi-23-ene-26,27-bishomo-25-hydroxyvitamin D3 (Ro-26-9228). Mol Endocrinol 18(4):874-87, 4/2004. PMID: 14726489.
18. Fizazi K, Yang J, Peleg S, Sikes CR, Kreimann EL, Daliani D, Olive M, Raymond KA, Janus TJ, Logothetis CJ, Karsenty G, Navone NM. Prostate cancer cells-osteoblast interaction shifts expression of growth/survival-related genes in prostate cancer and reduces expression of osteoprotegerin in osteoblasts. Clin Cancer Res 9(7):2587-97, 7/2003. PMID: 12855635.
19. Kittaka A, Kurihara M, Peleg S, Suhara Y, Takayama H. 2 alpha-(3-hydroxypropyl)- and 2 alpha-(3-hydroxypropoxy)-1 alpha,25-dihydroxyvitamin D3 accessible to vitamin D receptor mutant related to hereditary vitamin D-resistant rickets. Chem Pharm Bull (Tokyo) 51(3):357-8, 3/2003. PMID: 12612432.
20. Peleg S, Ismail A, Uskokovic MR, Avnur Z. Evidence for tissue- and cell-type selective activation of the vitamin D receptor by Ro-26-9228, a noncalcemic analog of vitamin D3. J Cell Biochem 88(2):267-73, 2/2003. PMID: 12520525.
21. Posner GH, Woodard BT, Crawford KR, Peleg S, Brown AJ, Dolan P, Kensler TW. 2,2-Disubstituted analogues of the natural hormone 1 alpha,25-dihydroxyvitamin D3: chemistry and biology. Bioorg Med Chem 10(7):2353-65, 7/2002. PMID: 11983533.
22. Rehan VK, Torday JS, Peleg S, Gennaro L, Vouros P, Padbury J, Rao DS, Reddy GS. 1Alpha,25-dihydroxy-3-epi-vitamin D3, a natural metabolite of 1alpha,25-dihydroxy vitamin D3: production and biological activity studies in pulmonary alveolar type II cells. Mol Genet Metab 76(1):46-56, 5/2002. PMID: 12175780.
23. Peleg S, Uskokovic M, Ahene A, Vickery B, Avnur Z. Cellular and molecular events associated with the bone-protecting activity of the noncalcemic vitamin D analog Ro-26-9228 in osteopenic rats. Endocrinology 143(5):1625-36, 5/2002. PMID: 11956143.
24. Posner GH, Halford BA, Peleg S, Dolan P, Kensler TW. Conceptually new low-calcemic oxime analogues of the hormone 1 alpha,25-dihydroxyvitamin D3: synthesis and biological testing. J Med Chem 45(8):1723-30, 4/2002. PMID: 11931627.
25. Posner GH, Crawford KR, Peleg S, Welsh JE, Romu S, Gewirtz DA, Gupta MS, Dolan P, Kensler TW. A non-calcemic sulfone version of the vitamin D3 analogue seocalcitol (EB 1089): chemical synthesis, biological evaluation and potency enhancement of the anticancer drug adriamycin. Bioorg Med Chem 9:2365-71, 9/2001. PMID: 11553477.
26. Gardezi SA, Nguyen C, Malloy PJ, Posner GH, Feldman D, Peleg S. A rationale for treatment of hereditary vitamin D-resistant rickets with analogs of 1 alpha,25-dihydroxyvitamin D3. J Biol Chem 276:29148-56, 8/2001. PMID: 11369766.
27. White MC, Burke MD, Peleg S, Brem H, Posner GH. Conformationally restricted hybrid analogues of the hormone 1 alpha,25-dihydroxyvitamin D3: design, synthesis, and biological evaluation. Bioorg Med Chem 9:1691-9, 7/2001. PMID: 11425569.
28. Yang J, Fizazi K, Peleg S, Sikes CR, Raymond AK, Jamal N, Hu M, Olive M, Martinez LA, Wood CG, Logothetis CJ, Karsenty G, Navone NM. Prostate cancer cells induce osteoblast differentiation through a Cbfa1-dependent pathway. Cancer Res 61:5652-9, 7/2001. PMID: 11454720.
29. Liu YY, Nguyen C, Ali Gardezi SA, Schnirer I, Peleg S. Differential regulation of heterodimerization by 1alpha,25-dihydroxyvitamin D3 and its 20-epi analog. Steroids 66:203-12, 3/2001. PMID: 11179727.
30. Siu-Caldera ML, Rao DS, Astecker N, Weiskopf A, Vouros P, Konno K, Fujishima T, Takayama H, Peleg S, Reddy GS. Tissue specific metabolism of 1alpha,25-dihydroxy-20-epi-vitamin D3 into new metabolites with significant biological activity: studies in rat osteosarcoma cells (UMR 106 and ROS 17/2.8). J Cell Biochem 82:599-609, 2001. PMID: 11500938.
31. Liu YY, Nguyen C, Peleg S. Regulation of ligand-induced heterodimerization and coactivator interaction by the activation function-2 domain of the vitamin D receptor. Mol Endocrinol 14:1776-87, 11/2000. PMID: 11075811.
32. Posner GH, Crawford K, Siu-Caldera ML, Reddy GS, Sarabia SF, Feldman D, van Etten E, Mathieu C, Gennaro L, Vouros P, Peleg S, Dolan PM, Kensler TW. Conceptually new 20-epi-22-oxa sulfone analogues of the hormone 1alpha,25-dihydroxyvitamin D3: synthesis and biological evaluation. J Med Chem 43:3581-6, 9/2000. PMID: 11000014.
33. Norman AW, Manchand PS, Uskokovic MR, Okamura WH, Takeuchi JA, Bishop JE, Hisatake JI, Koeffler HP, Peleg S. Characterization of a novel analogue of 1alpha,25(OH)2-vitamin D3 with two side chains: interaction with its nuclear receptor and cellular actions. J Med Chem 43:2719-30, 7/2000. PMID: 10893309.
34. Lee NE, Williard PG, Brown AJ, Campbell MJ, Koeffler HP, Peleg S, Rao DS, Reddy GS. Synthesis and biological activities of the two C23 epimers of 1alpha,23,25-trihydroxy-24-oxo-19-nor-vitamin D3: novel analogs of 1alpha,23(S),25-trihydroxy-24-oxo-vitamin D3, a natural metabolite of 1alpha,25-dihydroxyvitamin D3. Steroids 65:252-65, 5/2000. PMID: 10751637.
35. Siu-Caldera ML, Sekimoto H, Peleg S, Nguyen C, Kissmeyer AM, Binderup L, Weiskopf A, Vouros P, Uskokovic MR, Reddy GS. Enhanced biological activity of 1alpha,25-dihydroxy-20-epi-vitamin D3, the C-20 epimer of 1alpha,25-dihydroxyvitamin D3, is in part due to its metabolism into stable intermediary metabolites with significant biological activity. J Steroid Biochem Mol Biol 71:111-21, 12/1999. PMID: 10659699.
36. Posner GH, Wang Q, Han G, Lee JK, Crawford K, Zand S, Brem H, Peleg S, Dolan P, Kensler TW. Conceptually new sulfone analogues of the hormone 1alpha, 25-dihydroxyvitamin D3: synthesis and preliminary biological evaluation. J Med Chem 42:3425-35, 9/1999. PMID: 10479276.
37. Posner GH, Lee JK, Wang Q, Peleg S, Burke M, Brem H, Dolan P, Kensler TW. Noncalcemic, antiproliferative, transcriptionally active, 24-fluorinated hybrid analogues of the hormone 1alpha, 25-dihydroxyvitamin D3. Synthesis and preliminary biological evaluation. J Med Chem 41:3008-14, 7/1998. PMID: 9685240.
38. Peleg S, Nguyen C, Woodard BT, Lee JK, Posner GH. Differential use of transcription activation function 2 domain of the vitamin D receptor by 1,25-dihydroxyvitamin D3 and its A ring-modified analogs. Mol Endocrinol 12:525-35, 4/1998. PMID: 9544988.
39. Peleg S, Qiu H, Reddy S, Harris D, Van Q, Estey EH, Talpaz M, Estrov Z. 1,25-Dihydroxyvitamin D3 and its analogues inhibit acute myelogenous leukemia progenitor proliferation by suppressing interleukin-1beta production. J Clin Invest 100:1716-24, 10/1997. PMID: 9312169.
40. Liu YY, Collins ED, Norman AW, Peleg S. Differential interaction of 1alpha,25-dihydroxyvitamin D3 analogues and their 20-epi homologues with the vitamin D receptor. J Biol Chem 272:3336-45, 2/1997. PMID: 9013574.
41. Siu-Caldera ML, Clark JW, Santos-Moore A, Peleg S, Liu YY, Uskokovic MR, Sharma S, Reddy GS. 1alpha,25-dihydroxy-24-oxo-16-ene vitamin D3, a metabolite of a synthetic vitamin D3 analog, 1alpha,25-dihydroxy-16-ene vitamin D3, is equipotent to its parent in modulating growth and differentiation of human leukemic cells. J Steroid Biochem Mol Biol 59:405-12, 12/1996. PMID: 9010346.
42. Peleg S, Liu YY, Reddy S, Horst RL, White MC, Posner GH. A 20-epi side chain restores growth-regulatory and transcriptional activities of an A ring-modified hybrid analog of 1 alpha, 25-dihydroxyvitamin D3 without increasing its affinity to the vitamin D receptor. J Cell Biochem 63:149-61, 11/1996. PMID: 8913867.
43. Monla YT, Peleg S, Gagel RF, Monia YT [corrected to Monla YT]. Cell type-specific regulation of transcription by cyclic adenosine 3,'5'-monophosphate-responsive elements within the calcitonin promoter. Mol Endocrinol 9:784-93, 7/1995. PMID: 7476962.
44. Peleg S, Sastry M, Collins ED, Bishop JE, Norman AW. Distinct conformational changes induced by 20-epi analogues of 1 alpha,25-dihydroxyvitamin D3 are associated with enhanced activation of the vitamin D receptor. J Biol Chem 270:10551-8, 5/1995. PMID: 7737990.
45. Peleg S. Modified binding of proteins from calcitonin-negative tumor cells to the neuroendocrine-specific CANNTG motif of the calcitonin gene. Nucleic Acids Res 21:5360-5, 11/1993. PMID: 8265349.
46. Peleg S, Abruzzese RV, Cooper CW, Gagel RF. Down-regulation of calcitonin gene transcription by vitamin D requires two widely separated enhancer sequences. Mol Endocrinol 7:999-1008, 8/1993. PMID: 8232320.
47. Cote GJ, Stolow DT, Peleg S, Berget SM, Gagel RF. Identification of exon sequences and an exon binding protein involved in alternative RNA splicing of calcitonin/CGRP. Nucleic Acids Res 20:2361-6, 5/1992. PMID: 1594453.
48. Peleg S, Abruzzese RV, Cote GJ, Gagel RF. Transcription of the human calcitonin gene is mediated by a C cell-specific enhancer containing E-box-like elements. Mol Endocrinol 4:1750-7, 11/1990. PMID: 2280775.
49. Peleg S, Schrader WT, O'Malley BW. Differential sensitivity of chicken progesterone receptor forms to sulfhydryl reactive reagents. Biochemistry 28:7373-9, 9/1989. PMID: 2819076.
50. Peleg S, Cote GJ, Abruzzese RV, Gagel RF. Transcriptional regulation of the human calcitonin gene: a progress report. Henry Ford Hosp Med J 37:194-7, 1989. PMID: 2639134.
51. Peleg S, Schrader WT, O'Malley BW. Sulfhydryl group content of chicken progesterone receptor: effect of oxidation on DNA binding activity. Biochemistry 27:358-67, 1/1988. PMID: 3349038.
52. Peleg S, Schrader WT, Edwards DP, McGuire WL, O'Malley BW. Immunologic detection of a protein homologous to chicken progesterone receptor B subunit. J Biol Chem 260:8492-501, 7/1985. PMID: 2409088.
53. Peleg S. The modulation of decidual cells proliferation and differentiation by progesterone and prostaglandins. J Steroid Biochem 19:283-9, 7/1983. PMID: 6411982.
54. Markoff E, Zeitler P, Peleg S, Handwerger S. Characterization of the synthesis and release of prolactin by an enriched fraction of human decidual cells. J Clin Endocrinol Metab 56:962-8, 5/1983. PMID: 6300179.
55. Peleg S, Lindner HR. The effect of prostaglandins on progestin receptor translocation and on decidual cell reaction in vivo and in vitro. Endocrinology 110:1647-52, 5/1982. PMID: 6951711.
56. Peleg S, Lindner HR. Role of steroid hormones and prostaglandins in the regulation of DNA synthesis by decidual cells in culture. Mol Cell Endocrinol 20:209-18, 12/1980. PMID: 7202833.
57. Peleg S, De Boever J, Kaye AM. Replenishment and nuclear retention of oestradiol-17 beta receptors in rat uteri during postnatal development. Biochim Biophys Acta 587(1):67-74, 9/1979. PMID: 486547.
58. Peleg S, Bauminger S, Lindner HR. Oestrogen and progestin receptors in deciduoma of the rat. J Steroid Biochem 10:139-45, 2/1979. PMID: 513725.
59. Bauminger S, Peleg S. Changes in immunological activity of rat lymphoid organs during pregnancy. Clin Exp Immunol 32:179-85, 4/1978. PMID: 149623.
60. Globerson A, Bauminger S, Abel L, Peleg S. Decidual extracts suppress antibody response in vitro. Eur J Immunol 7:120-2, 2/1977. PMID: 872864.
61. Marcus ZH, Soffer Y, Ben-David A, Peleg S, Nebel L. Studies on sperm antigenicity: Delayed hypersensitivity to spermatozoa. Eur J Immunol 3:75-8, 2/1973. PMID: 4715666.

Invited Articles
1. Peleg S, Posner GH. Vitamin D analogs as modulators of vitamin D receptor action. Curr Top Med Chem 3(14):1555-72, 2003. PMID: 14683515.
2. Vickery BH, Avnur Z, Uskokovic M, Peleg S. A novel tissue-selective vitamin D receptor modulator. Vitamin D Endocrine System: Structural, Biological, Genetic and Clinical Aspects:887-892, 2000.
3. Posner GH, Crawford K, Peleg S, Dolan P, Kensler TW. Conceptually new 20-epi-22-oxa-26-sulfone synthetic analogs of the natural hormone 1alpha,25-dihydroxyvitamin D3. Vitamin D Endocrine System: Structural, Biological, Genetic and Clinical aspects:3-10, 2000.
4. Gardezi A, Nguyen C, Malloy PJ, Feldman D, Peleg S. Development of a rational strategy for the treatment of hereditary vitamin D resistant rickets with analogs of 1,25-dihydroxyvitamin D3. Vitamin D Endocrine System: Structural, Biological, Genetic and Clinical aspects:931-934, 2000.
5. Peleg S, Liu YY. Differential regulation of heterodimerization and coactivator interaction by the activation function 2 domain of the vitamin D receptor. In: Norman AW, Bouillon R, Thomasset. Vitamin D Endocrine System: Structural, Biological, Genetic and Clinical Aspects:291-296, 2000.
6. Peleg S, Liu YY, Reddy S, Collins ED, Norman AW. Differential interaction of 1alpha,25-dihydroxyvitamin D3 and its 20-epi analog with transcription activation function 2 (AF-2) domain of the vitamin D receptor. Vitamin D: Chemistry, Biology and Clinical Applications of the Steroid Hormone:203-209, 1997.
7. Peleg S, Nguyen C, Lee JK, Posner GH. Restoration of transcriptional activity by the addition of 16-ene and 26,27-bishomo to the A ring analog 1beta-hydroxymethyl-3-epi-25-hydroxyvitamin D3. Vitamin D: Chemistry, Biology and Clinical Applications of the Steroid Hormone, 1997.
8. Uskokovic MR, Manchand PS, Peleg S, Norman AW. Synthesis and preliminary evaluation of the biological properties of a 1alpha,25-dihydroxyvitamin D3 analog with two side-chains. Vitamin D: Chemistry, Biology and Clinical Applications of the Steroid Hormone:19-21, 1997.
9. Peleg S, Sastry M, Collins E, Bishop J, Norman AW. Differential activation of the vitamin D receptor (VDR) by 1alpha,25-dihydroxyvitamin D3 and its analogs. Vitamin D: Molecular, Cellular and Clinical Endocrinology, 1994.
10. Peleg S, Pike W, O'Malley BW. Detection of heterogeneity at the 5' end of the mouse vitamin D receptor transcripts. Calcium Regulation and Bone Metabolism, Basic and Clinical Aspects 10:168-173, 1990.
11. Peleg S, Pike W, O'Malley BW. Characterization of the chromosomal mouse vitamin D receptor gene. Vitamin D: Molecular, Cellular and Clinical Endocrinology:242-243, 1988.
12. Peleg S, Lindner HR. Inhibitory effects of indomethacin on nuclear binding of progesterone in the uterus and on differentiation of decidual cells in culture. Cellular and Molecular Aspects of Implantation:431-433, 1981.

Abstracts
1. Peleg S. calcitriol (1,25-dihydroxyvitamin D3) and dietary calcium induce distinct molecular changes and opposite cellular responses in colonic crypts hyperplasia. The University of Texas, M. D. Anderson Cancer Center, Annual Research Retreat of the Division of Internal Medicine, 2008.
2. Peleg S. The contribution of transgenic human vitamin D receptor (hVDR) expression in the proximal small intestine of VDR-null mice to calcium homeostasis and bone mineralization. 14th Annual Meeting on Vitamin D, 6/2007.
3. Peleg S. Identifying Structural Requirements for Vitamin D Analogs (Deltanoids) with High Growth-inhibitory Potential and Low Calcemic Activity. The University of Texas Division of Internal Medicine Annual Retreat, 5/2007.
4. Marks HD, Xue Y, Fleet JC, and Peleg S. Transgenic expression of the human vitamin D receptor (hVDR) in the proximal small intestine of VDR-null mice restores vitamin D-responsive active calcium absorption and prevents age-dependent decline in utilization of calcium-and lactose-rich diet. Bone Disease Program of Texas Annual Retreat, 4/2007.
5. Peleg S, Hsieh JC, Haussler MR. The importance of nuclear import in protection of the vitamin D receptor (VDR) from ubiquitination and proteasome-mediated degradation. The 13th Workshop on Vitamin D, Victoria, British Columbia. Oral Presentation, 4/2006.
6. Marks HD, Fleet JC, and Peleg S. Transgenic expression of the human vitamin D receptor (VDR) in duodenum of vdr-null mice attenuates age-dependent decline in calcium absorption. The 13th Workshop on Vitamin D, Victoria, British Columbia. Oral presentation. Young Investigator Award to Hilary D. Marks, 4/2006.
7. Peleg S, Cody DD, Navone N, Johnson E, and Posner GH. Differential response of osteolytic and osteoblastic bone metastases to vitamin D analogs. The 12th International Workshop on Calcified Tissues and Stem Cell Research, Herzliya, Israel. Oral presentation, 3/2006.
8. Peleg S, Chen L, Hu M, Avnur Z, Yang D. Regulation of duodenal response to 1,25-dihydroxyvitamin D3 in osteopenic rats. 11th International Workshop on Calcified Tissues, Israel, Oral presentation, 1999.
9. Peleg S, Avnur Z, Yang D. A tissue-specific action of an analog of 1,25-dihydroxyvitamin D3 promotes anabolic effects in bone without hypercalcemia. 2nd Joint Meeting of the ASBMR and IBMS, San Francisco, CA, 1998.
10. Peleg S, Avnur Z, Yang D. Mechanisms that promote anabolic effects of a vitamin D analog in bone without hypercalcemia. 80th annual Meeting of the Endocrine Society, New Orleans, 1998.

Book Chapters
1. Peleg S. Molecular Basis for Differential Action of Vitamin D3 Analogs. In: Vitamin D. 2, Second Edition. Ed(s) David Feldman, J. Wesley Pike and Francis H. Glorieux. Elsevier Academic Press, Capter 83, 1471-1488, 2005.
2. Peleg S. Molecular Basis for Differential Action of Vitamin D3 Analogs. In: Vitamin D. Chapter 60, 1011-1026, 1997.
3. Gagel RF, Peleg S. Thyroidal C-cells and Medullary Thyroid Carcinoma as Target Tissues for Vitamin D Action. In: Vitamin D. Ed(s) David Feldman, J. Wesley Pike and Francis H. Glorieux. Elsevier Academic Press, 369-378, 1997.
4. Gagel RF, Peleg S, Robinson M, Boyd III AE. Molecular mechanisms involved in the multiple endocrine neoplasia syndromes. In: Molecular Genetics of Nervous System Tumors. Wiley-Liss Inc, 271-281, 1993.
5. Peleg S, Cote GJ, Gagel RF. Transcriptional and posttranscriptional regulation of calcitonin gene expression. In: Cellular and Molecular Biology of Bone. Academic Press Inc. Harcourt Brace Jovanovich, 343-373, 1993.

Last updated: 10/5/2010